<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65477">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01947738</url>
  </required_header>
  <id_info>
    <org_study_id>VBY-891-001</org_study_id>
    <nct_id>NCT01947738</nct_id>
  </id_info>
  <brief_title>Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)</brief_title>
  <official_title>A Two-Part, Double-Blind, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-891 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virobay Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virobay Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is an inflammatory autoimmune disease that might be controlled by a cathepsin S
      inhibitor like VBY-891.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Refer to Brief Summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability of VBY-891</measure>
    <time_frame>For 7 days (single dose) or 17 days (multiple dose)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare number of adverse events experienced by male versus female subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VBY-891 Blood Levels</measure>
    <time_frame>3 days (single dose) or 10 days (multiple dose)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of VBY-891 levels in blood after single or multiple doses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Iip10 Accumulation and Cathepsin S Protein Level</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Iip10 accumulation and cathepsin S protein level by Mass Spectrophotometry to determine inhibition of cathepsin S activity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>VBY-891</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VBY-891</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules containing excipient but no active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBY-891</intervention_name>
    <description>Cathepsin S inhibitor</description>
    <arm_group_label>VBY-891</arm_group_label>
    <other_name>VBY-891</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-60 years old

          -  Screening body mass index between 18-32 kg/m2

          -  Good health, no clinically significant findings in medical history, 12-lead ECG, &amp;
             vital signs;

          -  Clinical lab evaluations (Chem panel [fasted at least 8 hrs], CBC, HbA1c &amp; UA in
             reference range for test lab (unless deemed not clinically significant);

          -  Negative test for drugs of abuse at Screening &amp; at Check-in (includes alcohol);

          -  Negative hepatitis, HIV &amp; TB screens;

          -  Females non-pregnant, non-lactating, &amp; either postmenopausal for at least 1 year,
             surgically sterile for at least 90 days prior to Check-in, or agree to use from the
             time of consent until 90 days after Study Completion an effective form of
             contraception.   For all females, a pregnancy test result must be negative at
             Screening &amp; Check-in.

          -  Males will be sterile or agree to use from Check-in until 90 days following discharge
             an effective method of contraception.

          -  Able to comprehend &amp; willing to sign Informed Consent Form

        Exclusion Criteria:

          -  Females pregnant or nursing, or childbearing potential but unwilling to use
             contraception.

          -  History of renal or hepatic impairment; stomach or intestinal surgery or resection,
             malabsorption syndrome, cholecystectomy, or gastro-intestinal dysfunction that would
             alter absorption &amp;/or excretion of orally administered drugs (appendectomy or hernia
             repair allowed);

          -  Anemia (hemoglobin &lt;11.5 g/dL for females; &lt; 13 g/dL for males) or blood donation
             within 8 weeks of Check-in;

          -  Plasma donation within 4 weeks of Check-in;

          -  History of alcoholism or drug addiction within 6 months to Check-in;

          -  Use of drugs of abuse or prescription drugs for recreational use 6 months prior to
             Check-in;

          -  Use of any tobacco-containing or nicotine-containing products 6 months prior to
             Check-in &amp; during study;

          -  Participation in another drug trial 30 days of Check-in (within 8 weeks if previous
             investigational drug has immunomodulatory effects, other than cathepsin S
             inhibition);

          -  History or clinical manifestations of metabolic, hepatic, renal, hematological,
             pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric
             disorders

          -  History of hypersensitivity or allergies to any drug compound

          -  History or presence of abnormal ECG

          -  Laboratory abnormality deemed clinically significant;

          -  Use of or inability to discontinue any prescription medications/products 14 days
             prior to Check-in &amp; during study;

          -  Use of certain over-the-counter, non-prescription preparations are permitted up to 3
             days before first dose;

          -  Use of alcohol-containing, grapefruit-containing, star fruit containing foods or
             beverages or &quot;energy drinks&quot; 72 hours to Check-in &amp; during study;

          -  Poor peripheral venous access;

          -  Receipt of blood products 6 months to Check-in

          -  Subjects with history of Gilbert's Syndrome;

          -  Strenuous activities 48 hours to Check-in

          -  Illness 5 days to drug administration

          -  Any acute or chronic condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B. Karpf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Virobay Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Evansville</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 27, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Subjects</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>VBY891</keyword>
  <keyword>Maximum</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Pharmacokinetic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
